Drugs / Decitabine/Cedazuridine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05636514 | Dec 2022 → Aug 2026 overdue | acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome | Clinical Hub for Interventional Research (CHOIR) | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Decitabine/Cedazuridine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05636514 ↗ |
| Route | Oral | “Decitabine/Cedazuridine 35 Mg-100 Mg ORAL TABLET” NCT05636514 ↗ |